Anavex Life Sciences Corp (AVXL)
Drugs • Health Care
August 03, 2026 Anavex Life Sciences Announces Board Refresh to Enhance Stockholder Value Anavex Life Sciences has announced a refreshed Board of Directors to enhance stockholder value, nominating two new independent members. The company's focus remains on advancing its lead candidate for Alzheimer’s while addressing ongoing stockholder concerns amidst a competitive landscape.
July 30, 2026 Anavex Life Sciences Reports Positive Developments in Financial Performance and Clinical Programs Anavex Life Sciences Corp. reported improved financial results for Q2 2026, with a cash balance of $127.4 million and reduced net losses. The company is advancing its lead compound, blarcamesine, through critical FDA submissions for Alzheimer's and other CNS disorders.
May 22, 2026 Anavex Life Sciences Faces Nasdaq Compliance Challenge Anavex Life Sciences Corp. faces a Nasdaq compliance challenge after failing to file its Form 10-Q on time. The company has until July 20, 2026, to rectify this issue and assures investors of its commitment to compliance and maintaining stock stability.
May 06, 2026 Anavex Life Sciences Appoints Dr. Terrie Kellmeyer as Interim CEO Amid Leadership Transition Anavex Life Sciences has appointed Dr. Terrie Kellmeyer as Interim CEO following the resignation of Christopher Missling. With extensive experience in the biopharmaceutical sector, Dr. Kellmeyer aims to advance Anavex’s innovative therapies for neurological disorders during this leadership transition.
April 14, 2026 Anavex Life Sciences Unveils Groundbreaking Research Linking Autism and Alzheimer's Disease Anavex Life Sciences has revealed a biological connection between autism spectrum disorder and Alzheimer’s disease, focusing on autophagy dysfunction. Their promising drug candidate, blarcamesine, targets these shared pathways, aiming to develop effective treatments for both conditions.
April 07, 2026 Anavex Life Sciences to Showcase Innovations at Needham Virtual Healthcare Conference Anavex Life Sciences will present its innovative drug candidates at the 25th Annual Needham Virtual Healthcare Conference. Highlighting treatments for Alzheimer’s and other CNS disorders, the company aims to improve patient outcomes through promising therapies like blarcamesine.
March 30, 2026 Anavex Life Sciences Provides Comprehensive Regulatory Update Anavex Life Sciences has withdrawn its EU marketing authorization for blarcamesine, focusing on enhancing data for early Alzheimer's treatment. The company is also engaging with the FDA to align its drug development efforts, showing its commitment to addressing neurodegenerative diseases.
March 25, 2026 Anavex Life Sciences Withdraws EU Application for Blarcamesine in Early Alzheimer’s Disease Treatment Anavex Life Sciences has withdrawn its EU application for blarcamesine as a treatment for early Alzheimer's disease following feedback from regulatory authorities. Despite this setback, the company remains dedicated to advancing its clinical development and addressing the unmet needs of patients.
March 23, 2026 Anavex Life Sciences Unveils Promising Data on Blarcamesine for Alzheimer's Treatment Anavex Life Sciences presented promising data on blarcamesine at the AD/PD 2026 Conference, highlighting its efficacy in early Alzheimer's and the preservation of brain volume. The study indicates significant clinical relevance, particularly for genetically defined patient groups, reinforcing Anavex's commitment to innovative Alzheimer's treatments.
March 20, 2026 Anavex Life Sciences Unveils Groundbreaking Findings on Alzheimer's Disease Mechanisms Anavex Life Sciences has revealed significant research indicating that autophagy failure is an early trigger for Alzheimer's disease. The study emphasizes the role of amyloid beta and tau interaction, suggesting new therapeutic avenues for treatment.
March 17, 2026 Anavex Life Sciences Achieves Major Breakthrough in Parkinson's Disease Treatment Anavex Life Sciences announced promising results for its drug blarcamesine in treating Parkinson's disease at the AD/PD 2026 Conference. The study showed improvements in motor function and dopaminergic nerve fiber density, highlighting the drug's potential as a disease-modifying treatment.
March 03, 2026 Anavex Life Sciences Corp. Set to Present at Citizens Life Sciences Conference Anavex Life Sciences Corp. will present at the Citizens Life Sciences Conference on March 10, 2026, highlighting its innovative CNS therapies. The company is making strides in treating Alzheimer's and Parkinson's diseases with its lead candidate, ANAVEX®2-73, while also exploring new therapeutic avenues.
February 25, 2026 Anavex Life Sciences Set to Showcase Innovation at the TD Cowen Annual Health Care Conference Anavex Life Sciences will showcase its innovative CNS treatments at the TD Cowen Annual Health Care Conference on March 2, 2026. CEO Christopher U Missling, PhD, will present insights on their lead drug candidates, including ANAVEX®2-73 and ANAVEX®3-71, aimed at treating Alzheimer's, Parkinson's, and Rett syndrome.
February 23, 2026 Anavex Life Sciences Welcomes Dr. Axel Paeger to Board of Directors Anavex Life Sciences has appointed Dr. Axel Paeger to its Board of Directors, bringing extensive healthcare leadership experience. His expertise is expected to enhance the company's strategic focus on developing innovative therapies for neurological disorders like Alzheimer's and Parkinson's.
February 09, 2026 Anavex Life Sciences Reports Q1 2026 Financial Results and Strategic Updates Anavex Life Sciences has reported its Q1 2026 financial results, highlighting its commitment to developing therapies for neurodegenerative diseases. The company focuses on blarcamesine for Alzheimer's and Parkinson's, with significant regulatory engagement and financial stability.
February 09, 2026 Anavex Life Sciences Corp. Reports Q1 2026 Financial Results: A Step Forward in CNS Therapeutics Anavex Life Sciences Corp. reported a significant reduction in net loss for Q1 2026, reflecting improved financial health. The company advances its CNS therapeutic pipeline, particularly ANAVEX®2-73 for Alzheimer’s and ANAVEX®3-71 for schizophrenia, while exploring strategic partnerships for future growth.
February 03, 2026 Anavex Life Sciences Set to Reveal Q1 2026 Financial Results Anavex Life Sciences is set to announce its Q1 2026 financial results on February 9, 2026. The conference call will provide insights into their clinical developments and financial performance, particularly focusing on their promising therapies for neurodegenerative disorders.
January 13, 2026 Anavex Life Sciences Corp. Joins ACCESS-AD Initiative to Tackle Alzheimer’s Disease Anavex Life Sciences Corp. is collaborating with ACCESS-AD to improve Alzheimer’s disease management through innovative therapies, including blarcamesine. This initiative aims to address the pressing need for effective treatment options as Alzheimer's prevalence rises in Europe.
January 08, 2026 Anavex Life Sciences Welcomes Neurology Expert Wolfgang Liedtke as Senior VP Anavex Life Sciences has appointed Dr. Wolfgang Liedtke as Senior VP, Global Head of Neurology, to strengthen its efforts in developing treatments for CNS disorders. With over 25 years of experience, Dr. Liedtke aims to enhance patient outcomes through innovative therapies.
January 06, 2026 Anavex Life Sciences Corp. Receives FDA Feedback on Alzheimer’s Disease Program Anavex Life Sciences Corp. received encouraging feedback from the FDA on its Alzheimer’s disease program, particularly regarding its drug candidate, blarcamesine. The FDA's collaborative approach opens pathways for Anavex to submit data for regulatory approval, addressing the critical need for effective Alzheimer's treatments.
December 18, 2025 Anavex Life Sciences Requests EMA Re-Examination for Blarcamesine in Alzheimer's Treatment Anavex Life Sciences has formally requested the EMA to re-evaluate its investigational Alzheimer's drug, blarcamesine, highlighting the urgent need for new treatment options. This move comes as the demand for effective therapies for Alzheimer's disease continues to escalate globally.
December 12, 2025 Anavex Life Sciences Faces Regulatory Setback in the EU for Alzheimer’s Treatment Blarcamesine Anavex Life Sciences Corp. recently announced a negative opinion from the EU's CHMP regarding its Alzheimer’s drug Blarcamesine. The company plans to request a re-examination of this decision, emphasizing its commitment to addressing the urgent need for effective Alzheimer’s treatments.
December 04, 2025 Anavex Life Sciences Corp Faces Fraud Investigation Amid Regulatory Setbacks Anavex Life Sciences Corp. is under investigation for potential securities law violations following a negative EMA vote on its lead drug, blarcamesine. The stock plummeted over 35%, raising concerns about the company's future and regulatory transparency. Investors are urged to stay informed as the situation develops.
November 26, 2025 Anavex Life Sciences Set to Showcase Blarcamesine Data at CTAD 2025 Anavex Life Sciences will showcase its groundbreaking blarcamesine data at the CTAD 2025 Conference, highlighting its potential benefits for early Alzheimer’s patients. Key presentations will focus on clinical trial insights, cognitive aging comparisons, and enhancing patient care.
November 25, 2025 Anavex Life Sciences Reports Fourth Quarter Results and Strategic Updates Anavex Life Sciences has reported its fourth quarter results for fiscal 2025, highlighting the development of blarcamesine for Alzheimer’s disease. The company showcased a commitment to addressing neurodegenerative disorders with significant clinical advancements and a strategic financial approach, despite a net loss.
November 25, 2025 Anavex Life Sciences Corp Reports 2025 Annual Results: A Year of Clinical Advancements Amid Financial Challenges Anavex Life Sciences Corp. reports its 2025 annual results, showcasing significant clinical advancements in its drug trials despite ongoing financial challenges and losses. The company aims to establish strategic partnerships to transition towards revenue generation while continuing its focus on research and development.
November 19, 2025 Anavex Life Sciences to Showcase Innovations at J.P. Morgan Healthcare Conference Anavex Life Sciences will present its latest CNS treatment innovations, including ANAVEX®2-73, at the 44th Annual J.P. Morgan Healthcare Conference. This event is crucial for discussing advancements in healthcare and biopharmaceuticals.
November 18, 2025 Anavex Life Sciences Corp. Set to Announce Fourth Quarter Financial Results Anavex Life Sciences Corp. will announce its fourth-quarter financial results on November 25, 2025. Following the announcement, a management conference call will discuss the company's performance and ongoing clinical developments in CNS disorders.
November 14, 2025 Anavex Life Sciences Corp. Faces Regulatory Setback for Blarcamesine in Early Alzheimer's Disease Anavex Life Sciences Corp. announced a regulatory setback for its Alzheimer's drug, blarcamesine, following a negative trend vote from the CHMP. The company plans to seek a re-examination and enhance its application with biomarker data, emphasizing the urgent need for effective Alzheimer's treatments.
October 29, 2025 Anavex Life Sciences Reports Promising Findings for Blarcamesine in Alzheimer's Treatment Anavex Life Sciences announced promising results for blarcamesine, which showed significant cognitive improvements and a favorable safety profile in early Alzheimer's patients. The study indicated a substantial delay in disease progression, potentially enhancing patient quality of life.
October 10, 2025 Anavex Life Sciences Presents Breakthrough Findings at Alzheimer Europe Conference Anavex Life Sciences presented significant findings at the Alzheimer Europe Conference, highlighting their lead drug candidate blarcamesine's potential to improve Alzheimer’s care. The oral presentation emphasized convenience for patients and families, reflecting the company’s commitment to advancing dementia treatment.
October 02, 2025 Anavex Life Sciences Corp. Develops Once-Daily Oral Tablet for ANAVEX®3-71 Anavex Life Sciences Corp. has developed a once-daily oral tablet for ANAVEX®3-71, improving patient compliance and effectiveness in treating CNS disorders. The new formulation shows promising pharmacokinetics and safety profiles, positioning it as a significant advancement in the field.
October 02, 2025 Anavex Life Sciences Reports Promising Phase 2 Results for Schizophrenia Treatment Anavex Life Sciences announced promising Phase 2 results for ANAVEX®3-71 in treating schizophrenia, demonstrating a favorable safety profile and positive biomarker trends. The study indicates potential for addressing unmet medical needs in schizophrenia treatment.
September 30, 2025 Anavex Life Sciences Publishes Groundbreaking Findings on Oral Blarcamesine for Alzheimer’s Treatment Anavex Life Sciences has published groundbreaking findings on blarcamesine, a promising treatment for early Alzheimer’s disease. With a favorable safety profile and significant improvements in patient quality of life, this therapy could revolutionize care for genetically relevant populations. The company's commitment to ongoing research highlights its potential impact on Alzheimer's treatment.
August 12, 2025 Anavex Life Sciences Corp. Reports Q3 2025 Financial Results: A Closer Look at Progress and Challenges Anavex Life Sciences Corp. reported its Q3 2025 financial results, revealing a net loss of $13.24 million and ongoing investments in clinical trials for CNS diseases. Despite financial challenges, strategic partnerships and a strong clinical pipeline offer hope for future growth.
May 13, 2025 Anavex Life Sciences Corp. Reports Q2 2025 Financial Results: A Period of Strategic Development Amidst Ongoing Losses Anavex Life Sciences Corp. reported a net loss of $11.19 million for Q2 2025, an increase from the previous year. Despite financial challenges, the company advances its innovative pipeline, especially ANAVEX®2-73, showing promise in Alzheimer's and other CNS disorders.
March 31, 2025 Anavex Life Sciences Set to Showcase Innovations at the 24th Annual Needham Virtual Healthcare Conference Anavex Life Sciences is set to showcase its latest innovations at the 24th Annual Needham Virtual Healthcare Conference from April 7-10, 2025. CEO Christopher U. Missling will present the company's advancements in treating neurodegenerative disorders, including promising drug candidates like ANAVEX®2-73. Investors are keenly anticipating insights on clinical progress and future strategies.
February 24, 2025 Anavex Life Sciences Set to Present at the 45th Annual TD Cowen Health Care Conference Anavex Life Sciences will present its innovative research at the 45th Annual TD Cowen Health Care Conference on March 3, 2025. CEO Christopher U Missling will discuss promising drug candidates like ANAVEX®2-73, aimed at treating CNS disorders, including Alzheimer's and Parkinson's diseases.
February 12, 2025 Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Business Update Anavex Life Sciences reported its Q1 2025 financial results, highlighting significant advancements in Alzheimer's treatment and a new patent issuance. Despite an increased net loss, the company maintains a strong cash position and commitment to R&D for neurodegenerative disorders.
February 12, 2025 Anavex Life Sciences Corp. Q1 2025 Financial Report: A Focus on Innovation Amidst Losses Anavex Life Sciences' Q1 2025 report highlights their commitment to advancing CNS treatments despite a net loss of $12.11 million. Their promising drug pipeline, especially ANAVEX2-73, reflects significant progress in clinical trials and regulatory submissions.
February 05, 2025 SWOT Analysis of Anavex Life Sciences Corp in 2025 This SWOT analysis of Anavex Life Sciences Corp reviews its strengths in intellectual property and innovative therapies for CNS disorders, while addressing financial vulnerabilities and competitive threats. The company has significant opportunities in the expanding CNS therapeutics market but must navigate operational challenges and regulatory hurdles.
February 05, 2025 Anavex Life Sciences Corp. Prepares for First Quarter Financial Results Release Anavex Life Sciences Corp. is set to announce its first-quarter financial results for 2025 on February 12. The company focuses on innovative treatments for neurodegenerative diseases, with key drug candidates in development. Investors can join a conference call for detailed insights into financial performance and strategic plans.
December 23, 2024 Anavex Life Sciences Corp. Reports 2024 Annual Financial Results Anavex Life Sciences Corp. reported a reduced net loss for fiscal 2024 while continuing to invest in R&D for CNS disorders. The company faces legal challenges but remains well-capitalized to support its innovative drug pipeline.
August 06, 2024 Anavex Life Sciences Corp. Reports Q3 2024 Financial Results: A Focus on Progress Amidst Challenges Anavex Life Sciences Corp. reported a net loss of $12.21 million for Q3 2024, reflecting increased R&D expenses. Despite financial challenges, significant advancements in clinical trials for CNS disorders signal a promising future for the company.
May 09, 2024 Anavex Life Sciences Corp. Q2 2024 Financial Report: A Mixed Bag Amid Promising Clinical Developments Anavex Life Sciences Corp. reports a net loss of $10.54 million for Q2 2024, despite promising clinical trial advancements for Alzheimer's and Rett syndrome. Their financial situation reflects ongoing operational challenges, but significant progress in drug development offers hope for future growth.